Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomised, Double-blind, Placebo-controlled, Multi-centre, International Study of MEDI4736 as Sequential Therapy in Patients With Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Definitive, Platinum-based, Concurrent Chemoradiation Therapy (PACIFIC)
Brief Summary: A Global Study to Assess the Effects of MEDI4736 following concurrent chemoradiation in Patients with Stage III Unresectable Non-Small Cell Lung Cancer.


Options:
A: Arm Label: Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin); Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Drug: Carboplatin, Drug: Nab-Paclitaxel | Arm Label: Arm B (Nab-Paclitaxel+Carboplatin); Type: ACTIVE_COMPARATOR; Interventions: Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Drug: Carboplatin, Drug: Nab-Paclitaxel, Drug: Pemetrexed | Intervention Type: DRUG; Name: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody; Assigned to Arm(s): Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin), Arm B (Nab-Paclitaxel+Carboplatin) | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin), Arm B (Nab-Paclitaxel+Carboplatin) | Intervention Type: DRUG; Name: Nab-Paclitaxel; Assigned to Arm(s): Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin), Arm B (Nab-Paclitaxel+Carboplatin) | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): Arm B (Nab-Paclitaxel+Carboplatin)
B: Arm Label: Arm A: Nivolumab; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab | Arm Label: Arm B: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab, Drug: Ipilimumab | Arm Label: Arm C: Nivolumab + Platinum doublet chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab, Drug: Carboplatin, Drug: Cisplatin, Drug: Gemcitabine, Drug: Pemetrexed, Drug: Paclitaxel | Arm Label: Arm D: Platinum doublet chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Cisplatin, Drug: Gemcitabine, Drug: Pemetrexed, Drug: Paclitaxel | Intervention Type: DRUG; Name: Nivolumab; Assigned to Arm(s): Arm A: Nivolumab, Arm B: Nivolumab + Ipilimumab, Arm C: Nivolumab + Platinum doublet chemotherapy | Intervention Type: DRUG; Name: Ipilimumab; Assigned to Arm(s): Arm B: Nivolumab + Ipilimumab | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm C: Nivolumab + Platinum doublet chemotherapy, Arm D: Platinum doublet chemotherapy | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Arm C: Nivolumab + Platinum doublet chemotherapy, Arm D: Platinum doublet chemotherapy | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Arm C: Nivolumab + Platinum doublet chemotherapy, Arm D: Platinum doublet chemotherapy | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): Arm C: Nivolumab + Platinum doublet chemotherapy, Arm D: Platinum doublet chemotherapy | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm C: Nivolumab + Platinum doublet chemotherapy, Arm D: Platinum doublet chemotherapy
C: Arm Label: Pembrolizumab + Chemotherapy Combo; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab, Drug: Paclitaxel, Drug: Nab-paclitaxel, Drug: Carboplatin | Arm Label: Placebo + Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Nab-paclitaxel, Drug: Carboplatin, Drug: Saline placebo for pembrolizumab | Intervention Type: BIOLOGICAL; Name: Pembrolizumab; Assigned to Arm(s): Pembrolizumab + Chemotherapy Combo | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Pembrolizumab + Chemotherapy Combo, Placebo + Chemotherapy | Intervention Type: DRUG; Name: Nab-paclitaxel; Assigned to Arm(s): Pembrolizumab + Chemotherapy Combo, Placebo + Chemotherapy | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Pembrolizumab + Chemotherapy Combo, Placebo + Chemotherapy | Intervention Type: DRUG; Name: Saline placebo for pembrolizumab; Assigned to Arm(s): Placebo + Chemotherapy
D: Arm Label: MEDI4736; Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 | Arm Label: PLACEBO; Type: PLACEBO_COMPARATOR; Interventions: Other: PLACEBO | Intervention Type: DRUG; Name: MEDI4736; Assigned to Arm(s): MEDI4736 | Intervention Type: OTHER; Name: PLACEBO; Assigned to Arm(s): PLACEBO

Answer: D